An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)

Trial Profile

An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Lonafarnib (Primary) ; Peginterferon alfa-2a; Ritonavir
  • Indications Hepatitis D
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms LOWR HDV-2; LOWR-2
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 05 Mar 2018 According to an Eiger BioPharmaceuticals media release, data will be presented as abstract at The International Liver Congress meeting April, 2018.
    • 27 Jul 2017 Status changed from recruiting to completed.
    • 21 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, data from the study has been presented at the The International Liver Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top